Semaglutide

Semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1RA) used to treat type 2 diabetes by enhancing insulin secretion, reducing appetite, and promoting weight loss. It is administered as a subcutaneous injection once weekly and has shown significant efficacy in improving glycemic control and reducing body weight.

Semaglutide and Type 2 Diabetes: Efficacy, Safety, and Outcomes

Semaglutide offers a multifaceted approach to type 2 diabetes treatment, enhancing insulin release and reducing blood sugar through glucagon suppression.

What's Next for Semaglutide? Beyond Diabetes and Weight Loss

New data reveals insights into cancer and cardiovascular safety of JAK inhibitors

Now, the work presented at the 2025 annual EULAR congress in Barcelona adds two important pieces to the puzzle.

12 Jun 2025

Tufts researchers design new generation of weight loss medications

Weight loss drugs like Ozempic and Wegovy are used by over 15 million adults in the U.S., or 4.5% of the population. Despite their effectiveness, they have drawbacks.

11 Jun 2025

Weight loss drug semaglutide proven safe and effective for people with schizophrenia

Diabetic weight loss medications are effective for people with schizophrenia without affecting psychotic symptoms, University of Queensland researchers have found.

10 Jun 2025

Real-world study finds lower weight loss with GLP-1 drugs due to early discontinuation

A Cleveland Clinic study shows that semaglutide and tirzepatide – injectable GLP-1 drugs for obesity – produce smaller weight loss in a real-world setting because patients discontinue treatment or use lower maintenance dosages.

10 Jun 2025

Leading health organizations release guidance on nutrition support for GLP-1 obesity therapies

Four leading organizations in lifestyle medicine, obesity medicine, and nutrition-the American College of Lifestyle Medicine (ACLM), the American Society for Nutrition (ASN), the Obesity Medicine Association (OMA), and The Obesity Society (TOS)-have jointly released a clinical advisory titled "Nutritional Priorities to Support GLP-1 Therapy for Obesity."

31 May 2025

Midlife weight loss may lower your long-term risk of diabetes, study finds

This study shows that midlife weight loss, without medical interventions, reduces chronic disease risk and supports longevity, beyond diabetes benefits.

29 May 2025

Researchers identify key nerve cells behind semaglutide's appetite reduction

A specific group of nerve cells in the brain stem appears to control how semaglutide affects appetite and weight – without causing nausea.

27 May 2025

Abdominal fat emerges as independent risk factor for psoriasis in women

Researchers have found that central body fat, especially around the abdomen, is more strongly linked to psoriasis risk than total body fat, particularly in women.

27 May 2025

MRI scans reveal why young women face higher risk for eating disorders

Advanced high-field MRI reveals distinct microstructural changes in hypothalamic subregions of young women with anorexia nervosa and obesity. These alterations may underlie increased vulnerability to eating disorders and point toward new neurobiological treatment targets.

26 May 2025

Brain stem nerve cells hold key to safer weight loss treatments

A specific group of nerve cells in the brain stem appears to control how semaglutide affects appetite and weight - without causing nausea

23 May 2025

Closed Loop Medicine appoints Kate Woolland as CEO

Closed Loop Medicine Ltd. (“CLM”), a leader in pharmaceutical precision dosing, today announced the appointment of Kate Woolland as Chief Executive Officer.

22 May 2025

Trump won’t force Medicaid to cover GLP-1S for obesity. A few states are doing it anyway.

When Page Campbell's doctor recommended she try an injectable prescription drug called Wegovy to lose weight before scheduling bariatric surgery, she readily agreed.

21 May 2025

Gut bacteria and genes jointly shape obesity risk, review reveals hidden links

Researchers examined the heritability of body mass index (BMI), highlighting that genetics and the gut microbiome both play major roles in obesity risk. The review emphasizes that maternal microbiome transmission and family environment may help explain “missing heritability” beyond known genetic factors.

20 May 2025

New approach directly combats the progression of Alzheimer’s and ALS

Scientists at Northwestern University have developed a new approach that directly combats the progression of neurodegenerative diseases like Alzheimer's disease and amyotrophic lateral sclerosis (ALS).

14 May 2025

Animal research reveals metabolic differences between tirzepatide and semaglutide

New animal research being presented at this year's European Congress on Obesity (ECO) in Malaga, Spain (11-14 May), reveals distinct metabolic adjustments to tirzepatide and semaglutide treatment, with tirzepatide temporarily increasing energy expenditure and semaglutide initially reducing energy expenditure.

14 May 2025

Once-daily oral treatment shows positive results in first human study for obesity treatment

A first-in-human study of an investigational once-daily oral treatment for obesity (SYNT-101) demonstrated positive preliminary data for the safe and effective redirection of nutrient absorption into the lower intestine, the weight loss and metabolic management mechanism behind gastric bypass surgery.

14 May 2025

Hormone FGF21 reverses fatty liver disease by signaling the brain

A pioneering research study published today in Cell Metabolism details how the hormone FGF21 (fibroblast growth factor 21) can reverse the effects of fatty liver disease in mice. The hormone works primarily by signaling the brain to improve liver function.

13 May 2025

Online obesity clinic achieves clinical trial-level weight loss with lower semaglutide doses

New research being presented at this year's European Congress on Obesity (ECO 2025) has found that patients of an online obesity clinic achieved similar weight loss to that reported in clinical trials – but with less than half the medication.

12 May 2025

Early cardiovascular benefits of semaglutide seen within months in SELECT trial

Semaglutide can rapidly reduce heart attacks and other serious cardiovascular complications in adults with overweight or obesity who have pre-existing cardiovascular disease but not diabetes, according to a secondary analysis of the landmark Semaglutide and Cardiovascular Outcomes (SELECT) trial from the same international author team being presented at this year's European Congress on Obesity (ECO) in Malaga, Spain.

12 May 2025

Study shows cardiovascular benefits of GLP-1RAs in patients following bariatric surgery

Medications like semaglutide and liraglutide may help to reduce the risk for heart attacks, strokes, and other major adverse cardiovascular events (MACE) as well as death in adults with obesity and diabetes following bariatric surgery who did not achieve sufficient weight loss and diabetes control, according to new research being presented at this year's European Congress on Obesity (ECO) in Malaga, Spain.

12 May 2025

Semaglutide

Overview

What's Next for Semaglutide? Beyond Diabetes and Weight Loss

Latest Semaglutide News and Research

New data reveals insights into cancer and cardiovascular safety of JAK inhibitors

Tufts researchers design new generation of weight loss medications

Weight loss drug semaglutide proven safe and effective for people with schizophrenia

Real-world study finds lower weight loss with GLP-1 drugs due to early discontinuation

Leading health organizations release guidance on nutrition support for GLP-1 obesity therapies

Midlife weight loss may lower your long-term risk of diabetes, study finds

Researchers identify key nerve cells behind semaglutide's appetite reduction

Abdominal fat emerges as independent risk factor for psoriasis in women

MRI scans reveal why young women face higher risk for eating disorders

Brain stem nerve cells hold key to safer weight loss treatments

Closed Loop Medicine appoints Kate Woolland as CEO

Trump won’t force Medicaid to cover GLP-1S for obesity. A few states are doing it anyway.

Gut bacteria and genes jointly shape obesity risk, review reveals hidden links

New approach directly combats the progression of Alzheimer’s and ALS

Animal research reveals metabolic differences between tirzepatide and semaglutide

Once-daily oral treatment shows positive results in first human study for obesity treatment

Hormone FGF21 reverses fatty liver disease by signaling the brain

Online obesity clinic achieves clinical trial-level weight loss with lower semaglutide doses

Early cardiovascular benefits of semaglutide seen within months in SELECT trial

Study shows cardiovascular benefits of GLP-1RAs in patients following bariatric surgery

Industry Focus: Cell & Gene Therapy eBook

Fluidics in Modern Healthcare & Medical Device Innovation

Scaling 3D biology: Automation, imaging, and the future of high-throughput research

How does norepinephrine influence anxiety-related behaviours?

Semaglutide

Overview

Latest Semaglutide News and Research

Industry Focus: Cell & Gene Therapy eBook

Fluidics in Modern Healthcare & Medical Device Innovation

Scaling 3D biology: Automation, imaging, and the future of high-throughput research

How does norepinephrine influence anxiety-related behaviours?

Newsletters you may be interested in